Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 18, 2024 - Issue
Submit an article Journal homepage
53
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Impact of Baohuoside I on the Metabolism of Tofacitinib in Rats

Yaru ShiKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui People’s Hospital, Lishui, Zhejiang, 323000, People’s Republic of China
,
Zebei LuKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui People’s Hospital, Lishui, Zhejiang, 323000, People’s Republic of China
,
Wei SongKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui People’s Hospital, Lishui, Zhejiang, 323000, People’s Republic of China
,
Yu WangKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui People’s Hospital, Lishui, Zhejiang, 323000, People’s Republic of China
,
Quan ZhouKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui People’s Hospital, Lishui, Zhejiang, 323000, People’s Republic of China
,
Peiwu GengKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui People’s Hospital, Lishui, Zhejiang, 323000, People’s Republic of China
,
Yunfang ZhouKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui People’s Hospital, Lishui, Zhejiang, 323000, People’s Republic of China
,
Shuanghu WangKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui People’s Hospital, Lishui, Zhejiang, 323000, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-0057-267X
ORCID Icon &
Aixia HanKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui People’s Hospital, Lishui, Zhejiang, 323000, People’s Republic of ChinaCorrespondence[email protected] [email protected]
 show all
Pages 931-939 | Received 22 Aug 2023, Accepted 13 Mar 2024, Published online: 25 Mar 2024

References

  • Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem. 2010;53(24):8468–8484. doi:10.1021/jm1004286
  • Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108–1123. doi:10.1002/art.41752
  • Palasik BN, Wang H. Tofacitinib, the first oral janus kinase inhibitor approved for adult ulcerative colitis. J Pharm Pract. 2021;34(6):913–921. doi:10.1177/0897190020953019
  • Dowty ME, Lin J, Ryder TF, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014;42(4):759–773. doi:10.1124/dmd.113.054940
  • Scott LJ. Tofacitinib: a review of its use in adult patients with rheumatoid arthritis. Drugs. 2013;73(8):857–874. doi:10.1007/s40265-013-0065-8
  • Lee JS, Kim SH. Dose-dependent pharmacokinetics of tofacitinib in rats: influence of hepatic and intestinal first-pass metabolism. Pharmaceutics. 2019;11(7):318. doi:10.3390/pharmaceutics11070318
  • Gupta P, Alvey C, Wang R, et al. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data. Br J Clin Pharmacol. 2012;74(1):109–115. doi:10.1111/j.1365-2125.2012.04168.x
  • Ma H, He X, Yang Y, et al. The genus Epimedium: an ethnopharmacological and phytochemical review. J Ethnopharmacol. 2011;134(3):519–541. doi:10.1016/j.jep.2011.01.001
  • Sun Y, Pang B, Wang Y, et al. Baohuoside I inhibits the proliferation of hepatocellular carcinoma cells via apoptosis signaling and NF-kB pathway. Chem Biodivers. 2021;18(6):e2100063. doi:10.1002/cbdv.202100063
  • Xi Y, Jiang T, Yu J, et al. Preliminary studies on the anti-osteoporosis activity of Baohuoside I. Biomed Pharmacother. 2019;115:108850. doi:10.1016/j.biopha.2019.108850
  • Kim B, Park B. Baohuoside I suppresses invasion of cervical and breast cancer cells through the downregulation of CXCR4 chemokine receptor expression. Biochemistry. 2014;53(48):7562–7569. doi:10.1021/bi5011927
  • Wang Q, Jiang S, Wang W, et al. Effects of baohuoside-I on epithelial-mesenchymal transition and metastasis in nasopharyngeal carcinoma. Hum Exp Toxicol. 2021;40(4):566–576. doi:10.1177/0960327120960765
  • Ma M, Fan AY, Liu Z, et al. Baohuoside I inhibits osteoclastogenesis and protects against ovariectomy-induced bone loss. Front Pharmacol. 2022;13:874952. doi:10.3389/fphar.2022.874952
  • Zhang LB, Yan Y, He J, et al. Epimedii Herba: an ancient Chinese herbal medicine in the prevention and treatment of rheumatoid arthritis. Front Chem. 2022;10:1023779. doi:10.3389/fchem.2022.1023779
  • Wang B, Shen J, Zhou Q, et al. Effects of naringenin on the pharmacokinetics of tofacitinib in rats. Pharm Biol. 2020;58(1):225–230. doi:10.1080/13880209.2020.1738504
  • Lawendy N, Lamba M, Chan G, et al. The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor. Clin Pharmacol Drug Dev. 2014;3(6):421–427. doi:10.1002/cpdd.143
  • Bae SH, Chang SY, Kim SH. Slower elimination of tofacitinib in acute renal failure rat models: contribution of hepatic metabolism and renal excretion. Pharmaceutics. 2020;12(8):714. doi:10.3390/pharmaceutics12080714
  • Ighani A, Georgakopoulos JR, Yeung J. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. G Ital Dermatol Venereol. 2020;155(4):400–410. doi:10.23736/S0392-0488.20.06643-2
  • Ma C, Battat R, Jairath V, et al. Advances in therapeutic drug monitoring for small-molecule and biologic therapies in inflammatory bowel disease. Curr Treat Options Gastroenterol. 2019;17(1):127–145. doi:10.1007/s11938-019-00222-9
  • Bae SH, Choi HG, Park SY, et al. Effects of isosakuranetin on pharmacokinetic changes of tofacitinib in rats with N-dimethylnitrosamine-induced liver cirrhosis. Pharmaceutics. 2022;14(12):2684. doi:10.3390/pharmaceutics14122684
  • Won JM, Choi HG, Park SY, et al. Effects of hyperlipidemia on the pharmacokinetics of tofacitinib, a JAK 1/3 inhibitor, in rats. Pharmaceutics. 2023;15(9):2195. doi:10.3390/pharmaceutics15092195
  • Gwak EH, Yoo HY, Kim SH. Effects of diabetes mellitus on the disposition of tofacitinib, a janus kinase inhibitor, in rats. Biomol Ther. 2020;28(4):361–369. doi:10.4062/biomolther.2020.006
  • Bettonte S, Berton M, Marzolini C. Magnitude of drug-drug interactions in special populations. Pharmaceutics. 2022;14(4):789. doi:10.3390/pharmaceutics14040789
  • Kristensen MB. Drug interactions and clinical pharmacokinetics. Clin Pharmacokinet. 1976;1(5):351–372. doi:10.2165/00003088-197601050-00003

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.